SBIR-STTR Award

Sensing Lead for Denoising Ambulatory Ecgs and False Positive Event Reduction
Award last edited on: 12/4/17

Sponsored Program
SBIR
Awarding Agency
NIH : NHLBI
Total Award Amount
$1,493,470
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Marina V Brockway

Company Information

VivaQuant LLC

4339 Nancy Place
Saint Paul, MN 55126
   (661) 765-0740
   N/A
   www.vivaquant.com
Location: Single
Congr. District: 04
County: Ramsey

Phase I

Contract Number: 1R43HL110739-01A1
Start Date: 6/22/12    Completed: 8/31/13
Phase I year
2012
Phase I Amount
$196,613
In-band artifact and noise present a major obstacle to extracting accurate, reliable, and repeatable information from ambulatory recordings of subcutaneous and surface ECGs. With more than 4 million patients a year experiencing ambulatory evaluations for cardiac arrhythmia, in-band artifact and noise is an urgent, wide-reaching challenge. In clinical care, for example, the high incidence of false positive arrhythmia detections can result in the need for expensive manual over-read, leading to poor operational efficiencies and higher cost of care. In addition, noise can mask P-waves, thereby preventing evaluation of atrial activity, an important factor in making the correct diagnosis and pursuing the most effective treatment strategy. This issue is also important in clinical research on drug safety and effectiveness (the basis for assessing public health impacts of new and approved medications) because noise introduces variability in interval measurements which, in turn, increases sample size and cost and also compromises the quality of information. Successful completion of this proposed multiphase SBIR research program will result in a universal ECG sensing lead that will provide relatively noise free signals for recording on commercially available ambulatory ECG monitors. This will result in a significant improvement in the quality of diagnostic information available to physicians that care for the 4 million patients that seek treatment for cardiac arrhythmias each year in the US. The improved diagnostic information will lead to more informed therapeutic decisions, improved patient quality of life, and higher quality care delivered at a lower cost. Specifically, Phase I will focus on researching approaches to optimization of a novel, proven, and patent- pending algorithm for removing in-band noise from ECG signals without compromising underlying signal morphology and fidelity, referred to as Multi-Domain FilteringTM. Innovative approaches will be researched to implement critical mathematical functions of this algorithm using efficient numerical methods and computational techniques. The algorithm will be implemented in embedded code and tested on targeted microprocessor systems to evaluate computational efficiency, power consumption, noise reduction performance, and fidelity. Testing will also be performed to estimate the impact of denoising on arrhythmia event detection accuracy when used with state-of-the-art ambulatory ECG monitoring devices.

Public Health Relevance:
Successful completion of this proposed multiphase SBIR research program will result in a universal ECG sensing lead that will provide relatively noise free signals for recording on commercially available ambulatory ECG monitors. This will result in a significant improvement in the quality of diagnostic information available to physicians that care for the 4 million patients that seek treatment for cardiac arrhythmias each year in the US. The improved diagnostic information will lead to more informed therapeutic decisions, improved patient quality of life, and higher quality care delivered at a lower cost.

Phase II

Contract Number: 9R44DA041815-02A1
Start Date: 7/1/11    Completed: 8/31/17
Phase II year
2015
(last award dollars: 2016)
Phase II Amount
$1,296,857

In-band artifact and noise present a major obstacle to efficient extraction of accurate, reliable, and repeatable information from ambulatory recordings of subcutaneous and surface ECGs. With more than 4 million patients a year experiencing ambulatory evaluations for cardiac arrhythmia, in-band artifact and noise is an urgent, wide-reaching challenge. In clinical care, for example, the high incidence of false positive arrhythmia detections resulting from noise and artifact can require expensive manual over-read, leading to poor operational efficiencies and higher cost of delivering care. Some manufacturers have attempted to address this issue in ambulatory event recorders by tuning the arrhythmia detection algorithm to increase positive predictive value (reduce false positive events) at the expense of decreased sensitivity, resulting in missed events and a reduction in diagnostic yield. In addition to inducing significant numbers of false positive events, noise can mask P-waves, rendering a definitive diagnosis of atrial fibrillation difficult. Noise also impacts studies of drg safety and effectiveness because noise introduces variability in risk markers which, in turn, increases sample size and cost and compromises the quality of information. To address this need, a novel miniature (15 cc) fully functioning Holter/event/mobile cardiac telemetry device will be developed in Phase II. This device employs the patented VivaQuant MDSP algorithm for real- time processing of ECGs. This algorithm provides for >26 dB reduction in in-band noise without distorting ECG morphology and provides superior event detection sensitivity and PPV, especially in noisy recordings. This Phase II effort will build upon a successful Phase I effort an will optimize algorithm power consumption and performance based upon numerical optimization strategies researched in Phase I. The remaining features including wireless communications, data compression, and symptomatic event recording will be implemented and tested in Phase II. At the completion of the Phase II effort, all testing to applicable standards and documentation will be completed and a 510k will be submitted to FDA. The Holter/event recorder developed in this multi-phase effort will result in a significant improvement in the quality of diagnostic information available to physicians, leading to better informed therapeutic decisions, improved patient quality of life, and higher-quality care delivered at a lower cost. The small size and othe patient-friendly features of the device will render it more comfortable to wear, leading to improved patient compliance and higher-quality diagnostic information. In addition, once the embedded algorithm is optimized, we will pursue partnerships to commercialize the MDSP algorithm in other applications where accurate ultra low-power ECG processing is required such as for implantable loop recorders, subcutaneous defibrillators, and neural stimulation devices.

Public Health Relevance Statement:


Public Health Relevance:
Successful completion of this proposed multiphase SBIR research program will result in a combination Holter/event recorder/mobile cardiac telemetry device for monitoring the 4 million ambulatory patients that seek treatment for arrhythmias each year. The proposed device will provide noise-free ECG recordings and includes several features that we hypothesize will significantly increase diagnostic yield compared to current devices. The improved diagnostic information will lead to more informed therapeutic decisions, improved patient quality of life, and higher quality care delivered at a lower cost.

Project Terms:
accurate diagnosis; Address; Algorithms; Arrhythmia; Atrial Fibrillation; base; Boston; Capital; Cardiac; Caring; Clinical; clinical care; Clinical Research; commercialization; Communication; Compliance behavior; Computer software; Consumption; cost; Data; Data Compression; Databases; Defibrillators; design; Detection; Development; Devices; Diagnosis; Diagnostic; Documentation; effective therapy; Effectiveness; EKG P Wave; Electrocardiogram; Electrodes; Evaluation; Event; experience; Future; Gel; Geographic Locations; Heart Atrium; Human; improved; Incidence; innovation; interest; Investments; Lead; Legal patent; Licensing; Life; Manuals; Manufacturer Name; Marketing; Masks; Measurement; meetings; Monitor; monitoring device; Morphologic artifacts; Morphology; National Heart, Lung, and Blood Institute; neural stimulation; Noise; novel; Patients; Performance; Pharmaceutical Preparations; Phase; Physicians; post-market; Predictive Value; Process; programs; prototype; public health medicine (field); public health relevance; Quality of Care; Quality of life; Reading; Research; research clinical testing; Risk Marker; Safety; Sales; Sample Size; Sampling Studies; Signal Transduction; Small Business Innovation Research Grant; Solutions; subcutaneous; Surface; Symptoms; System; Technology; Telemetry; Testing; Therapeutic; Time; treatment strategy; usability; Ventricular; Water; Wireless Technology